Parmax Pharma Ltd

Ms. Ami Shah has resigned as an Independent Director of Parmax Pharma Ltd, effective October 28, 2026. The resignation is attributed to a change in management following the acquisition of a majority stake and completion of an open offer. Ms. Shah confirmed there are no other material reasons for her departure beyond the change in management and control. The company is in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Mr. Nikhil Uchat has resigned as an Independent Director of Parmax Pharma Ltd. effective October 8, 2026. The resignation is attributed to a change in management following the acquisition of a majority stake and completion of an open offer. Mr. Uchat confirmed no other material reasons for his departure and stated he holds no directorships or committee memberships in other listed entities.

Parmax Pharma Ltd has announced the closure of its trading window for designated persons. This closure is in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The window will be shut from October 01, 2026, until 48 hours after the declaration of financial results for the quarter and half-year ending September 30, 2026. The specific date of the board meeting to consider these results will be communicated later.

Parmax Pharma Ltd reported a major fire incident at its plant in Rajkot, Gujarat, which occurred early on September 28, 2026. The fire was successfully controlled with the assistance of the Fire Department and plant employees. Two employees sustained injuries and have been hospitalized; no fatal casualties were reported. The extent of the damage is currently under assessment, but the losses are covered by insurance. The company has stated that it will keep the stock exchange informed of further material developments. The incident is expected to have an impact on production and operations, though specific details are still being evaluated.

Parmax Pharma Limited has announced its 32nd Annual General Meeting (AGM) scheduled for Tuesday, September 29, 2026, at 3:30 PM IST. The meeting will be conducted via Video Conferencing/Other Audio Visual Means. Key dates for e-voting include a cut-off date of September 22, 2026, with remote e-voting open from September 26 to September 28, 2026. The AGM agenda includes the adoption of the audited standalone financial statements for FY 2025-26, re-appointment of Shri Umang Gosalia as Director, and the appointment of Mr. Dhiren Chandulal Shah and Mr. Sunil Chinubhai Shah as Non-Executive Directors.

Parmax Pharma Limited has released its Annual Report for the Financial Year 2025-26 and the Notice for its 32nd Annual General Meeting (AGM). The AGM is scheduled for September 29, 2026, to be held via Video Conference. Key agenda items include the adoption of audited standalone financial statements for FY26 and the re-appointment of Shri Umang Gosalia as Director. Additionally, Mr. Dhiren Chandulal Shah is proposed for appointment as a Non-Executive Director and Chairman. The report also details corporate information, board composition, and auditor details.

Parmax Pharma Ltd has filed a disclosure under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, detailing changes in shareholding by Dhiren Shah and Persons Acting in Concert (PACs). The acquirers and PACs, considered part of the promoter group, have acquired 22,80,444 equity shares and 17,16,574 warrants pursuant to a preferential issue. This acquisition, approved by BSE, has altered their total holding. The filing provides a detailed breakdown of share and warrant acquisition before and after the transaction, impacting their overall stake in the company.

Parmax Pharma Ltd announced the allotment of 31,37,586 equity shares and 21,45,145 convertible warrants on a preferential basis to non-promoter category individuals. The equity shares were allotted at an issue price of ₹36.50 each, including a premium of ₹26.50. The convertible warrants are also priced at ₹36.50 each and are convertible into one equity share within 18 months. The total funds raised from the equity share allotment amount to ₹11,45,21,889. The company received in-principle approval from the stock exchange on August 21, 2026.

Parmax Pharma Limited has filed an intimation regarding the reclassification of its promoters under Regulation 31A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Following an Open Offer and a Share Purchase Agreement, certain individuals and entities will be classified as new promoters and promoter group members, while the erstwhile promoters will be reclassified under the Public Category. This move is in compliance with SEBI regulations, with undertakings provided by the parties involved confirming adherence to the stipulated conditions for reclassification.

Parmax Pharma Ltd has received 'In-Principle' Approval from BSE Limited for the issuance of equity shares and warrants on a preferential basis. The approval, granted under Regulation 28(1) of SEBI LODR Regulations, permits the issuance of 31,37,586 equity shares at a price of not less than ₹36.50 per share and 21,45,145 warrants convertible into equity shares at a price of not less than ₹36.50 per warrant. This approval is contingent upon compliance with applicable SEBI regulations. The company had previously intimated about this proposed issuance on June 8, 2026.